This conversation features Brian Magierski and a panel of scientists discussing the Gale Token and its focus on Galactin-3 as a drug target for Alzheimer’s disease. They explore the role of Galactin-3 in neuroinflammation, the challenges of drug development, and the mission of Cerebrum DAO to fund innovative research in brain diseases. The scientists share their backgrounds, the significance of their research, and the potential impact of their findings on future therapies. The discussion emphasizes the importance of community engagement and funding in advancing scientific research and clinical trials.
Cerebrum DAO is focused on funding research for brain diseases.
The Gale Token aims to support research on Galactin-3 as a drug target.
Galactin-3 plays a significant role in neuroinflammation and Alzheimer’s disease.
The scientists involved have extensive backgrounds in neurobiology and medicinal chemistry.
Challenges in drug development include blood-brain barrier penetration and selectivity.
The project aims to explore both systemic and direct brain administration of Galactin-3 inhibitors.
Community funding is essential for advancing research and clinical trials.
The potential for Galactin-3 inhibitors to be used in combination therapies is promising.
Future studies will focus on understanding microglial responses to Galactin-3 inhibition.
The project has a clear pathway toward clinical development and potential commercialization.
00:00 Introduction to Cerebrum DAO and the Gale Token
02:30 The Role of Galactin 3 in Alzheimer’s Disease
05:18 Research Background and Team Introductions
08:27 Galactin 3: Mechanisms in Health and Disease
11:10 Cerebrum DAO’s Mission and Funding Approach
14:28 Galactin 3 as a Therapeutic Target
17:26 The Future of Alzheimer’s Research and Galactin 3
19:10 Community Engagement and Research Funding
30:00 Challenges in Developing Galactin-3 Inhibitors
36:57 Overview of the Research Project
43:48 Next Steps in Research and Development
49:52 Community Engagement and Future Directions
Cerebrum DAO, Gale Token, Alzheimer’s disease, Galactin-3, neuroinflammation, brain diseases, drug development, community funding, clinical trials, therapeutic targets
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.